Quotes 5-day view Delayed Nyse
4 041 677
8 265 918
3 241 515
3 817 784
4 125 045
Estimated financial data (e) (USD)
27 480 M
Net income 2021
6 130 M
Net Debt 2021
12 164 M
P/E ratio 2021
27 860 M
Net income 2022
7 001 M
Net Debt 2022
9 715 M
P/E ratio 2022
EV / Sales 2021
EV / Sales 2022
Nbr of Employees
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The CompanyÔÇÖs products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products...
Ratings of Eli Lilly and Company
All news about ELI LILLY AND COMPANY
12/03 FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
12/03 Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody T..
12/03 Eli Lilly Gets FDA's Expanded Emergency Use Approval for Antibody Therapy to Treat COVI..
12/03 FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infant..
12/03 Eli Lilly Sees FDA Granting EUA of Two Monoclonal Antibodies for Treatment of COVID in ..
12/03 AbCellera Biologics Names New Chief Commercial Officer
12/03 Eli Lilly, Innovent Biologics' Cancer Drug Added to China's Updated National Reimbursem..
12/03 Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
12/02 Innovent Biologics, Inc. and Eli Lilly and Company Announce Successful Expansion of Sin..
12/02 Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
12/02 What COVID-19 vaccine and drug makers have to say about Omicron
12/01 Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment C..
11/30 US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
11/30 CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
11/30 Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr..
News in other languages on ELI LILLY AND COMPANY
Analyst Recommendations on ELI LILLY AND COMPANY
Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
Chart ELI LILLY AND COMPANY
Technical analysis trends ELI LILLY AND COMPANY
Short Term Mid-Term Long Term Trends Bearish Neutral Bullish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target